New data show positive results in individuals with a single F508del mutation as well as people with two copies of F508del and support continued development of triple combination therapies.
Site Search
Showing 1 - 10 of 208 results
News
|
|
1 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
6 min read
Our federal and state advocacy efforts support our mission of ensuring that everyone with cystic fibrosis has access to high-quality, specialized care. We evaluate policies and legislation through one lens: How would this impact people with CF and their families?
The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.
News
|
|
3 min read
This year, Cystic Fibrosis Advocates inspired new champions in Washington, D.C. and in state capitols across the country to take action on critical CF-related issues.
News
|
|
2 min read
News
|
|
1 min read